Document is current
Any future updates will be listed below
-
Authors
Benatar, Michael https://orcid.org/0000-0003-4241-5135
Wiendl, Heinz
Nowak, Richard
Zheng, Yan
Macias, William
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct05403541 at ClinicalTrials.govnct05403541 at ClinicalTrials.govDocuments that mention this clinical trial
Tumor-infiltrating CD163-positive macrophages and clinical outcomes to first-line nivolumab therapy in patients with advanced clear cell renal cell carcinoma (ccRCC) enrolled in the HCRN GU16-260 trial.
https://doi.org/10.1200/jco.2024.42.4_suppl.448
Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
https://doi.org/10.1136/bmjno-2023-000536
nct03863080 at ClinicalTrials.govDocuments that mention this clinical trial
Tumor-infiltrating CD163-positive macrophages and clinical outcomes to first-line nivolumab therapy in patients with advanced clear cell renal cell carcinoma (ccRCC) enrolled in the HCRN GU16-260 trial.
https://doi.org/10.1200/jco.2024.42.4_suppl.448
Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
https://doi.org/10.1136/bmjno-2023-000536
nct03863080 at ClinicalTrials.govDocuments that mention this clinical trial
Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
https://doi.org/10.1136/bmjno-2023-000536
nct05517447 at ClinicalTrials.govDocuments that mention this clinical trial
Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
https://doi.org/10.1136/bmjno-2023-000536
nct05517447 at ClinicalTrials.govDocuments that mention this clinical trial
Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
https://doi.org/10.1136/bmjno-2023-000536
nct05524571 at ClinicalTrials.govDocuments that mention this clinical trial
Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
https://doi.org/10.1136/bmjno-2023-000536
nct05524571 at ClinicalTrials.govDocuments that mention this clinical trial
Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
https://doi.org/10.1136/bmjno-2023-000536
nct05517421 at ClinicalTrials.govDocuments that mention this clinical trial
Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
https://doi.org/10.1136/bmjno-2023-000536
nct05517421 at ClinicalTrials.govDocuments that mention this clinical trial
Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
https://doi.org/10.1136/bmjno-2023-000536
nct05581199 at ClinicalTrials.govDocuments that mention this clinical trial
Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
https://doi.org/10.1136/bmjno-2023-000536
nct05581199 at ClinicalTrials.govDocuments that mention this clinical trial
Novel therapies in CIDP
https://doi.org/10.1136/jnnp-2024-334165
Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
https://doi.org/10.1136/bmjno-2023-000536
nct03922321 at ClinicalTrials.govDocuments that mention this clinical trial
Novel therapies in CIDP
https://doi.org/10.1136/jnnp-2024-334165
Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
https://doi.org/10.1136/bmjno-2023-000536
nct03938545 at ClinicalTrials.govDocuments that mention this clinical trial
Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
https://doi.org/10.1136/bmjno-2023-000536
nct03938545 at ClinicalTrials.govDocuments that mention this clinical trial
Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
https://doi.org/10.1136/bmjno-2023-000536
nct05039190 at ClinicalTrials.govDocuments that mention this clinical trial
Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
https://doi.org/10.1136/bmjno-2023-000536
nct05039190 at ClinicalTrials.govDocuments that mention this clinical trial
Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
https://doi.org/10.1136/bmjno-2023-000536
nct04650854 at ClinicalTrials.govDocuments that mention this clinical trial
Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
https://doi.org/10.1136/bmjno-2023-000536
nct04650854 at ClinicalTrials.govDocuments that mention this clinical trial
2634 Cyclical rozanolixizumab treatment in generalised myasthenia gravis (gMG): pooled analysis of MycarinG (Phase 3 study) and two open-label extension studies
https://doi.org/10.1136/bmjno-2023-anzan.65
Response to rozanolixizumab across treatment cycles in patients with generalised myasthenia gravis: post hoc analysis
https://doi.org/10.1136/jnnp-2024-abn.167
Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
https://doi.org/10.1136/bmjno-2023-000536
2999 Response to rozanolixizumab across treatment cycles in patients with generalised myasthenia gravis: a <i>post hoc</i> analysis
https://doi.org/10.1136/bmjno-2024-anzan.36
1 Rozanolixizumab treatment patterns in patients with generalised myasthenia gravis: post hoc analysis
https://doi.org/10.1136/jnnp-2025-abn.1
nct04951622 at ClinicalTrials.govDocuments that mention this clinical trial
2634 Cyclical rozanolixizumab treatment in generalised myasthenia gravis (gMG): pooled analysis of MycarinG (Phase 3 study) and two open-label extension studies
https://doi.org/10.1136/bmjno-2023-anzan.65
Response to rozanolixizumab across treatment cycles in patients with generalised myasthenia gravis: post hoc analysis
https://doi.org/10.1136/jnnp-2024-abn.167
Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
https://doi.org/10.1136/bmjno-2023-000536
2999 Response to rozanolixizumab across treatment cycles in patients with generalised myasthenia gravis: a <i>post hoc</i> analysis
https://doi.org/10.1136/bmjno-2024-anzan.36
1 Rozanolixizumab treatment patterns in patients with generalised myasthenia gravis: post hoc analysis
https://doi.org/10.1136/jnnp-2025-abn.1
nct04951622 at ClinicalTrials.govDocuments that mention this clinical trial
Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
https://doi.org/10.1136/bmjno-2023-000536
21 Long-term safety and efficacy of nipocalimab in generalized myasthenia gravis: vivacity-MG3 open-label extension phase results
https://doi.org/10.1136/jnnp-2025-abn.21
2581 Vivacity MG phase 3 study: clinical trial of nipocalimab administered to adults with generalized myasthenia gravis
https://doi.org/10.1136/bmjno-2023-anzan.39
Documents that mention this clinical trial
21 Long-term safety and efficacy of nipocalimab in generalized myasthenia gravis: vivacity-MG3 open-label extension phase results
https://doi.org/10.1136/jnnp-2025-abn.21
Batoclimab as induction and maintenance therapy in patients with myasthenia gravis: rationale and study design of a phase 3 clinical trial
https://doi.org/10.1136/bmjno-2023-000536
2581 Vivacity MG phase 3 study: clinical trial of nipocalimab administered to adults with generalized myasthenia gravis
https://doi.org/10.1136/bmjno-2023-anzan.39
-
Funding
Funding for this research was provided by:
Immunovant, Inc. (N/A)
- License Information
